Trials / Not Yet Recruiting
Not Yet RecruitingNCT04599543
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
Clinical Trial for the Safety and Efficacy of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.
Detailed description
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD123+ acute myeloid leukemia. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IL3 CAR T-cells | Each subject receive IL3 CAR T-cells by intravenous infusion |
Timeline
- Start date
- 2020-11-15
- Primary completion
- 2023-11-15
- Completion
- 2026-11-15
- First posted
- 2020-10-22
- Last updated
- 2020-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04599543. Inclusion in this directory is not an endorsement.